Cationic compounds with activity against multidrug-resistant bacteria: Interest of a new compound compared with two older antiseptics, hexamidine and chlorhexidine

Clinical Microbiology and Infection

Volumn 16, Issue 5, 2010, Pages 432-438

  Grare, M ^a   Dibama, H Massimba ^a   Lafosse, S ^a   Ribon, A ^a   Mourer, M ^a   Regnouf de Vains, J B ^a   Finance, C ^a   Duval, R E ^a  

^a NANCY UNIVERSITÉ   (France)

Author keywords

Antiseptics; Calixarene; Cationic compounds; Chlorhexidine; Hexamidine; Multidrug resistant bacteria; Nosocomial pathogens

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; BETA LACTAMASE; BETA LACTAMASE AMPC; CHLORHEXIDINE GLUCONATE; EXTENDED SPECTRUM BETA LACTAMASE; HEXAMIDINE ISETIONATE; PARA GUANIDINOETHYLCALIX[4]ARENE; PENICILLIN BINDING PROTEIN 2A; PROTEIN VAN; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG SCREENING; ENTEROBACTERIACEAE; ENZYME SYNTHESIS; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SENSITIVE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; YERSINIA ENTEROCOLITICA;

ACINETOBACTER BAUMANNII; BACILLI (CLASS); ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; YERSINIA ENTEROCOLITICA;

EID: 77952905843     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02837.x     Document Type: Article

References (20)

1. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol 2005, 99:703-715.
2. Kratzer C, Tobudic S, Graninger W, Buxbaum A, Georgopoulos A. In vitro antimicrobial activity of the novel guanidine Akacid Plus. J Hosp Infect 2006, 63:316-322.
3. Sheldon AT. Antiseptic " resistance": real or perceived threat? Clin Infect Dis 2005, 40:1650-1656.
4. Sekiguchi JI, Hama T, Fujino T. Detection of the antiseptic- and disinfectant-resistance gene qacA, qacB and qacC in Methicillin-Resistant Staphylococcus aureus isolated in a Tokyo hospital. Jpn J Infect Dis 2004, 57:288-291.
5. Sidhu MS, Heir E, Leegaard T, Wiger K, Holck A. Frequency of disinfectant resistance genes and genetic linkage with β-lactamase transposon Tn552 among clinical staphylococci. Antimicrob Agents Chemother 2002, 46:2797-2803.
6. Grare M, Mourer M, Fontanay S, Regnouf-de-Vains JB, Finance C, Duval RE. In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria. J Antimicrob Chemother 2007, 60:575-581.
7. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A6 2003, PA, USA, NCCLS Wayne
8. Communiqué 2008 (Edition janvier 2008) http://www.sfm.asso.fr/, (last accessed 1 February 2008)
9. Cui L, Murakami H, Kuwahara-Akai K, Hanaki H, Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000, 44:2276-2285.
10. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995, 33:24-27.
11. Del Vecchio VG, Petroziello JM, Gress MJ. Molecular genotyping of methicillin-resistant Staphylococcus aureus via fluorophore-enhanced repetitive-sequence PCR. J Clin Microbiol 1995, 33:2141-2144.
12. Mourer M, Duval RE, Finance C, Regnouf-de-Vains JB. Functional organisation and gain of activity: The case of the antibacterial para-guanidinoethylcalix[4]arene. Bioorg Med Chem Lett 2006, 16:2960-2963.
13. Crawford AG, Fuhr JP, Bhaskar R. Cost-benefit analysis of chlorhexidine gluconate dressing in the prevention of catheter-related bloodstream infections. Infect Control Hosp Epidemiol 2004, 25:668-674.
14. Block C, Furman M. Association between intensity of chlorhexidine use and micro-organisms of reduced susceptibility in a hospital environment. J Hosp Infect 2002, 51:201-206.
15. Buxbaum A, Kratzer C, Graninger W, Georgopoulos A. Antimicrobial and toxicological profile of the new biocide Akacid Plus®. J Antimicrob Chemother 2006, 58:193-197.
16. Irizarry L, Merlin T, Rupp J, Griffith J. Reduced susceptibility of methicillin-resistant Staphylococcus aureus to cetylpyridinium chloride and chlorhexidine. Chemotherapy 1996, 42:248-252.
17. Giannelli M, Chellini F, Margheri M, Tonelli P, Tani A. Effect of chlorhexidine digluconate on different cell types: a molecular and ultrastructural investigation. Toxicol In vitro 2007, 22:308-317.
18. Vollmer W, Blanot MA, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiol Rev 2008, 32:149-169.
19. Kandler O, Schleifer KH, Dandl R. Differentiation of Streptococcus faecalis Andrewes and Horder and Streptococcus faecium Orla-Jensen based on the amino acid composition of their murein. J Bacteriol 1968, 96:1935-1939.
20. Grare M, Lafosse S, Regnouf-de-Vains JB, Finance C, Duval RE. Interest of a fluorochrome-based flow cytometry approach to evaluate impact of antibacterial drugs on bacterial cell wall 2008, Washington, DC, USA, Abstract # F2-376, 48th ICAAC, 25-28 October